Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00727-4 · doi-reference
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
10.1056/evidoa2200015 · doi-reference
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
10.1016/s2468-1253(22)00043-7 · doi-reference
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
10.1002/ijc.33013 · doi-reference
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
10.1016/s1470-2045(20)30445-9 · doi-reference
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
10.1016/j.annonc.2022.05.519 · doi-reference
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · doi-reference
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
10.1158/2159-8290.cd-16-1000 · doi-reference
Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
10.1002/ijc.33230 · doi-reference
Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study
10.1200/jco.2022.40.16_suppl.3008 · doi-reference
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
10.1016/s1470-2045(20)30321-1 · doi-reference
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
10.1056/nejmoa1502309 · doi-reference
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
10.1056/nejmoa1714448 · doi-reference
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
10.1038/s41698-021-00206-y · doi-reference
Precision Oncology Targets in Biliary Tract Cancer
10.3390/cancers15072105 · doi-reference
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)
10.1200/jco.2022.40.16_suppl.4006 · doi-reference
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
10.1016/s1470-2045(23)00242-5 · doi-reference
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
10.1016/s1470-2045(22)00621-0 · doi-reference
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
10.1016/s1470-2045(21)00336-3 · doi-reference
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
10.1016/s2468-1253(22)00335-1 · doi-reference
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
10.1016/s1470-2045(20)30157-1 · doi-reference
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
10.21037/jgo.2019.03.10 · doi-reference
New Horizons for Precision Medicine in Biliary Tract Cancers
10.1158/2159-8290.cd-17-0245 · doi-reference
Cholangiocarcinoma - novel biological insights and therapeutic strategies
10.1038/s41571-023-00770-1 · doi-reference
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
10.1158/2159-8290.cd-21-0697 · doi-reference
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
10.1158/2159-8290.cd-19-0182 · doi-reference
Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01
10.1200/jco.2022.40.4_suppl.427 · doi-reference
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
10.1016/s2468-1253(21)00196-5 · doi-reference
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
10.1056/nejmoa2206834 · doi-reference
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
10.1016/s1470-2045(20)30109-1 · doi-reference
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
10.1093/annonc/mdt419 · doi-reference
Molecular targeted therapies: Ready for "prime time" in biliary tract cancer
10.1016/j.jhep.2020.03.007 · doi-reference
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
10.1158/1078-0432.ccr-14-3212 · doi-reference
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma
10.1245/s10434-023-13809-5 · doi-reference
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
10.1016/s1470-2045(18)30915-x · doi-reference
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
10.1002/bjs.10776 · doi-reference
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
10.1200/jco.18.00050 · doi-reference
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
10.1200/jco.2022.40.4_suppl.378 · doi-reference
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
10.1200/jco.2023.41.4_suppl.lba490 · doi-reference
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
10.1056/nejmoa0908721 · doi-reference
